Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis Inc (NUWE) is a leader in developing medical devices for fluid overload management and renal monitoring. This page serves as the definitive source for verified news and official announcements about the company’s innovations in critical care technology.
Access real-time updates on Aquadex SmartFlow System deployments, RenalSense Clarity RMS clinical validations, and strategic partnerships. Investors and healthcare professionals will find essential information about regulatory milestones, research findings, and operational developments directly impacting patient care standards.
Our curated collection includes earnings reports, product launch details, and peer-reviewed study outcomes. All content is rigorously verified to ensure accuracy while maintaining accessibility for both medical experts and general investors.
Bookmark this page for streamlined access to NUWE’s latest advancements in ultrafiltration therapy and kidney function monitoring technologies. Return regularly to stay informed about developments shaping the future of fluid management solutions.
Nuwellis has announced the issuance of a new patent for its pediatric continuous renal replacement therapy (CRRT) device, Vivian™, from the USPTO. The patent includes innovations such as self-centering fluid bag hangers, density compensation mechanisms, and self-sealing access ports, enhancing fluid management accuracy, ease of use, and system reliability. Vivian™'s new features streamline dialysis modes and secure seals, reducing leak risks. This is the second of several patents for Vivian™, underscoring Nuwellis' dedication to improving treatment for critically ill children. Nestor Jaramillo, President and CEO, highlighted this development as a significant milestone in pediatric CRRT.
Nuwellis has announced the extension of its pilot collaboration with DaVita for the Aquadex® ultrafiltration therapy, aimed at adult patients with congestive heart failure, until August 31, 2024. This partnership allows further evaluation of the Aquadex SmartFlow system in high-need patients within select U.S. markets. DaVita, a leading kidney care provider, may extend the agreement for up to 10 years, signifying a potential long-term collaboration in inpatient and outpatient ultrafiltration services. The goal is to enhance patient care through innovative medical solutions.
Nuwellis, a medical tech firm, announced on May 14, 2024, the expansion of its pediatric ultrafiltration program using the Aquadex SmartFlow System at a major hospital network in Florida. This initiative expands their current service, which caters to adult heart failure and critical care patients, to include pediatric patients.
Currently, seven hospitals within this network use Nuwellis' technology. This expansion enhances fluid management strategies across the healthcare system for all age groups.
The Aquadex system, FDA-cleared for both adults and pediatric patients over 20 kg, safely removes excess fluid from patients unresponsive to conventional diuretics. The device features customizable fluid removal rates and real-time hematocrit monitoring, important for pediatric care.
Nuwellis, Inc. (Nasdaq: NUWE) has announced a purchase agreement with a top 25 integrated delivery network in the U.S., involving 50 hospitals, to provide Aquadex Ultrafiltration Therapy. This agreement aims to expand access to advanced ultrafiltration technology for heart failure, critical care, and pediatric patients, demonstrating a commitment to innovative treatment options.
Nuwellis, Inc. reported financial results for Q1 2024 with revenue of $1.9 million, a 2% increase over the prior year. Consumables sales grew by 11%, pediatric revenue increased by 40%, and gross margin improved to 64.1%. The company received FDA clearance for a new catheter and launched Aquadex ultrafiltration therapy. Expense reductions of nearly 50% are expected for the rest of the year.
Nuwellis, Inc. (Nasdaq: NUWE) has received a Notice of Allowance from the USPTO for a patent related to its innovative pediatric Continuous Renal Replacement Therapy (CRRT) device Vivian™. This patent enhances Nuwellis' IP portfolio, enabling healthcare providers to seamlessly switch between stationary and transport modes for improved patient care. The company is also developing a new pediatric CRRT device with NIH funding, in collaboration with Koronis Biomedical Technologies , to better care for children with kidney issues.
Nuwellis, Inc. announced the closing of a $2.7 million public offering, issuing 11,250,000 shares of common stock and warrants. The gross proceeds will be used for working capital and general corporate purposes, including investments in commercialization efforts.
Nuwellis, Inc. (NUWE) will report its first quarter 2024 financial results on May 7, 2024. The medical technology company will host a conference call and webcast to discuss the results and provide a business update.
FAQ
What is the current stock price of Nuwellis (NUWE)?
What is the market cap of Nuwellis (NUWE)?
